2022 has ended, and major pharmaceutical companies have begun to disclose their 2022 performance forecasts
one after another.
According to combing, as of January 3, a total of 9 biopharmaceutical companies have issued performance forecasts, of which 8 are developing well, and the net profit growth rate of 3 listed companies is expected to be more than
100%.
Jardine Jardine is expected to achieve a net profit of 351 million yuan to 407 million yuan in 2022, a year-on-year increase of 140.
85% to 179.
67%.
According to the data, Jardine Matheson's proprietary products include household non-invasive ventilators, ventilation masks, sleep monitors, high-flow humidified oxygen therapy devices, oxygen generators, and provide respiratory health chronic disease management services
.
In response to investors' questions recently, Jardine Matheson said that the company will continue to strengthen internal management, actively carry out market development, steadily and orderly increase sales and form scale effects, and strive to reduce production costs
under the premise of ensuring quality and quantity.
The construction of the company's "annual output of 300,000 ventilators and 3.
5 million sets of accessories project" aims to improve the automation level of the production process, improve production efficiency, realize the unified coordination of product design, process research and development, processing and manufacturing, quality inspection and other processes, and improve product quality consistency and full traceability
。 The company's "marketing network and brand building project" (domestic construction of 3,000 retail counters and 500 after-sales service outlets, the establishment of 4 branches abroad), aims to increase the radiation penetration of the target market, further enhance the company's marketing capabilities, and further enhance the company's international market competitiveness
.
Chuanning Biotech expects net profit growth of 243% to 269% in 2022 and 243% to 269%
year-on-year.
Chuanning Biotech expects to achieve operating income ranging from 3.
656 billion yuan to 3.
769 billion yuan in 2022, a year-on-year increase of 13% to 17%; The net profit attributable to shareholders of the company ranges from 382 million yuan to 411 million yuan, which is expected to increase by 243% to 269%
year-on-year.
The data shows that Chuanning biological antibiotic intermediates have a complete range of products, covering the main intermediates
of macrolides and broad-spectrum antibiotics.
For the performance growth, Chuanning Biotech explained two reasons: first, the short suspension of production due to the epidemic in the fourth quarter of 2021, resulting in a low profit level in 2021; Second, the selling prices of major products are expected to show an upward trend compared with the same period last year in 2022, of which the average sales price of erythromycin thiocyanate is expected to increase by 18%, the average sales unit price of 6-APA is expected to increase by about 41%, and the average sales unit price of penicillin G potassium salt is expected to increase by about 63%.
In addition to special reasons, the considerable performance returns are also inseparable from the company's continuous investment in research and development
.
After years of technology accumulation, Chuanning Biotechnology has formed a number of independent intellectual property rights technologies such as antibiotic fermentation technology, enzymatic reaction technology, and "three wastes" disposal technology, which has laid a solid foundation
for the company to expand its influence in the global antibiotic industry chain.
Shanwaishan is expected to make a profit of 42.
39 million yuan to 63.
58 million yuan in 2022, with a growth rate of 117.
68% to 226.
5%.
According to the data, Shanwaishan is mainly engaged in the research and development, production and sales of blood purification equipment and consumables, and provides chain hemodialysis medical services
.
Driven by the unabated demand for localization of blood purification equipment, Shanwaishan's performance in the reporting period and even in 2022 has achieved rapid growth, and it is expected that the net profit attributable to the parent in 2022 is expected to reach at least 121.
13% and above
.
In the industry's view, with the continuous increase in the popularity of blood purification, medical dialysis and other treatment methods, this is expected to bring more definitive support
to the subsequent performance growth and valuation logic of Shanwaishan.
At present, Shanwaishan has formed a whole industrial chain system layout such as blood purification equipment, blood purification consumables and chain hemodialysis center, and has established scientific and technological innovation platforms
such as national enterprise technology center, national postdoctoral research workstation, and national and local joint engineering research center.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
